Sutureless aortic valve replacement was associated with significantly lower 30-day mortality and one-year mortality rates compared to transcatheter aortic valve replacement.
Does sutureless aortic valve replacement improve mortality and valvular leakage compared to transcatheter aortic valve replacement in symptomatic patients with aortic stenosis?
In symptomatic patients with aortic stenosis, SU-AVR offers similar in-hospital and 2-year mortality to TAVR, but may reduce 30-day mortality, 1-year mortality, and valvular leakage.
Absolute Event Rate: 0% vs 0%
BACKGROUND: The efficacy and safety of a novel aortic valve replacement treatment (SAVR) technique, sutureless aortic valve replacement (SU-AVR), compared to transcatheter aortic valve replacement (TAVR) in the treatment of aortic stenosis, is unclear in short and mid-term outcomes due to limited data. METHODS: PubMed, Scopus, Embase, Web of Science, and the Cochrane Library were systematically searched for studies comparing SU-AVR with TAVR. Risk ratios (RR) with 95 % confidence intervals (CIs) were computed for binary outcomes. Trial sequential analysis (TSA) was performed to assess whether the results in our meta-analysis were conclusive. RESULTS: This systematic review and meta-analysis included 22 observational studies of symptomatic patients. When comparing SU-AVR to TAVR, similar risk of in-hospital mortality (RR 0.67, 95 % CI 0.37-1.24, p = 0.20, I CONCLUSION: In patients with aortic stenosis, SU-AVR was associated with similar in-hospital mortality and two-year mortality rates compared with TAVR; however, it was associated with significantly lower 30-day mortality, total number of valvular leakages, and one-year mortality rates.
Obi et al. (Wed,) reported a other. Sutureless aortic valve replacement was associated with significantly lower 30-day mortality and one-year mortality rates compared to transcatheter aortic valve replacement.